Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATRA Atara Biotherapeutics	$8.01 -2.9%	$7.79	$5.01 ▼ $18.71	$50.46M	0.18	118,246 shs	18,894 shs
ATYR aTyr Pharma	$5.25 -0.5%	$4.38	$1.48 ▼ $5.98	$472.61M	0.89	1.24 million shs	2.38 million shs
LFCR Lifecore Biomedical	$8.03 -0.1%	$7.05	$3.68 ▼ $8.63	$297.68M	0.71	228,151 shs	55,721 shs
MRSN Mersana Therapeutics	$0.29 +3.7%	$0.35	$0.26 ▼ $2.83	$36.08M	0.79	2.71 million shs	1.86 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATRA Atara Biotherapeutics	0.00%	+0.63%	-3.84%	+43.29%	+3.89%
ATYR aTyr Pharma	0.00%	+4.45%	+2.22%	+100.53%	+525,399,900.00%
LFCR Lifecore Biomedical	0.00%	-1.95%	+16.72%	+51.80%	+62.88%
MRSN Mersana Therapeutics	0.00%	-0.34%	-21.41%	-4.26%	-84.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATRA Atara Biotherapeutics	4.1187 of 5 stars	3.3	3.0	4.7	0.6	2.5	0.6
ATYR aTyr Pharma	2.6326 of 5 stars	3.6	2.0	0.0	2.6	1.7	0.6
LFCR Lifecore Biomedical	1.0488 of 5 stars	1.3	2.0	0.0	1.1	4.2	0.6
MRSN Mersana Therapeutics	3.6845 of 5 stars	3.5	1.0	4.1	1.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	121.60% Upside
ATYR aTyr Pharma	3.14	Buy	$20.20	284.47% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	-0.37% Downside
MRSN Mersana Therapeutics	3.00	Buy	$5.20	1,693.10% Upside

Current Analyst Ratings Breakdown

Latest ATRA, LFCR, ATYR, and MRSN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/4/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
6/3/2025	MRSN Mersana Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/19/2025	ATYR aTyr Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/16/2025	MRSN Mersana Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
5/16/2025	MRSN Mersana Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$3.00
5/6/2025	MRSN Mersana Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$4.00 ➝ $3.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATRA Atara Biotherapeutics	$199.73M	0.24	N/A	N/A	($16.89) per share	-0.47
ATYR aTyr Pharma	$230K	2,033.07	N/A	N/A	$0.83 per share	6.33
LFCR Lifecore Biomedical	$128.26M	2.32	N/A	N/A	$0.37 per share	21.70
MRSN Mersana Therapeutics	$40.50M	0.89	N/A	N/A	($0.08) per share	-3.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	-7.83%	N/A	-14.51%	8/11/2025 (Estimated)
ATYR aTyr Pharma	-$64.02M	-$0.81	N/A	N/A	N/A	N/A	-87.09%	-64.77%	8/12/2025 (Estimated)
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-35.90%	-551.09%	-13.89%	8/15/2025 (Estimated)
MRSN Mersana Therapeutics	-$69.19M	-$0.59	N/A	N/A	N/A	-217.63%	-990.16%	-48.87%	8/12/2025 (Estimated)

Latest ATRA, LFCR, ATYR, and MRSN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/15/2025	Q1 2025	MRSN Mersana Therapeutics	-$0.21	-$0.19	+$0.02	-$0.19	$6.05 million	$2.75 million
5/7/2025	Q1 2025	ATYR aTyr Pharma	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
MRSN Mersana Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATRA Atara Biotherapeutics	N/A	0.57	0.57
ATYR aTyr Pharma	0.01	7.79	7.79
LFCR Lifecore Biomedical	66.36	2.71	1.59
MRSN Mersana Therapeutics	N/A	1.83	1.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATRA Atara Biotherapeutics	70.90%
ATYR aTyr Pharma	61.72%
LFCR Lifecore Biomedical	83.36%
MRSN Mersana Therapeutics	93.92%

Insider Ownership

Company	Insider Ownership
ATRA Atara Biotherapeutics	4.00%
ATYR aTyr Pharma	3.70%
LFCR Lifecore Biomedical	32.20%
MRSN Mersana Therapeutics	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
ATYR aTyr Pharma	53	89.00 million	85.71 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	25.10 million	Optionable
MRSN Mersana Therapeutics	150	124.63 million	108.43 million	Optionable

ATRA, LFCR, ATYR, and MRSN Headlines

Recent News About These Companies

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Buy" by Brokerages

July 5 at 2:23 AM | americanbankingnews.com

Mersana Therapeutics Settles Debt with Oxford Finance

July 3 at 4:48 PM | tipranks.com

Mersana Therapeutics Inc (MRSN) - Investing.com

July 2 at 11:49 AM | investing.com

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

Mersana Therapeutics to Present at Upcoming Investor Conferences

May 20, 2025 | globenewswire.com

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Call Transcript

May 16, 2025 | insidermonkey.com

Q1 2025 Mersana Therapeutics Inc Earnings Call

May 16, 2025 | uk.finance.yahoo.com

Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ...

May 16, 2025 | finance.yahoo.com

Mersana extends cash runway into mid-2026 as restructuring narrows focus to breast cancer

May 15, 2025 | msn.com

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 15, 2025 | finance.yahoo.com

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 15, 2025 | globenewswire.com

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

May 15, 2025 | zacks.com

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 15, 2025 | finance.yahoo.com

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 15, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and IQVIA Holdings (IQV)

May 9, 2025 | theglobeandmail.com

Mersana Therapeutics announces strategic cutbacks amid economic pressures

May 7, 2025 | investing.com

Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC

May 6, 2025 | fiercebiotech.comF

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

May 6, 2025 | globenewswire.com

Why Mersana Therapeutics, Inc.’s (MRSN) Stock Is Down 8.13%

May 2, 2025 | aaii.comA

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

April 23, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA, LFCR, ATYR, and MRSN Company Descriptions

Atara Biotherapeutics NASDAQ:ATRA

$8.01 -0.24 (-2.91%)

Closing price 07/3/2025 03:37 PM Eastern

Extended Trading

$8.32 +0.31 (+3.86%)

As of 07/3/2025 04:01 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

aTyr Pharma NASDAQ:ATYR

$5.25 -0.03 (-0.49%)

Closing price 07/3/2025 03:55 PM Eastern

Extended Trading

$5.21 -0.04 (-0.84%)

As of 07/3/2025 04:59 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Lifecore Biomedical NASDAQ:LFCR

$8.03 -0.01 (-0.12%)

As of 07/3/2025 01:04 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Mersana Therapeutics NASDAQ:MRSN

$0.29 +0.01 (+3.68%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$0.30 +0.01 (+1.72%)

As of 07/3/2025 04:59 PM Eastern

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time